Trial Profile
REPORT; REirradiation and PD-1 Blockade On Recurrent Squamous Cell Head and Neck Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms REPORT
- 26 Oct 2017 New trial record